About the GFI and its evolution

With a long-term commitment to addressing infertility, Merck created the GFI, integrating both drugs and technologies within fertility management strategies in a patient-centred way to ultimately reduce the time to live birth. The GFI showcased Merck’s dedication in the area of human reproduction; however, it also revealed a need for more thorough and wider support that extends beyond funding and includes participation in a collaborative network of experts.

The MIP for human reproduction is a successor of the GFI. It is a new program that adopts collaborative, cross-functional and cost-effective research approaches, aiming to support innovative research translation. It is not only a source of funding, but a program developed using cutting-edge digital technologies, simplifying project administration and enabling connections among different stakeholders.

The MIP drives innovation by following an efficient translational approach, tracking key performance indicators and enhancing collaboration and co-creation across geographies and time zones at all phases of development, in order to bridge the translational gap. With the MIP, Merck’s focus shifts from a unilateral approach to open innovation, that leverages both internal and external expertise, thus driving the aim to address unmet medical needs in human reproduction and ultimately deliver products to improve patient outcomes for couples.